Last reviewed · How we verify
Passiflora incarnata
Passiflora incarnata contains alkaloids and flavonoids that modulate GABAergic and monoaminergic neurotransmission to produce anxiolytic and sedative effects.
Passiflora incarnata contains alkaloids and flavonoids that modulate GABAergic and serotonergic neurotransmission to produce anxiolytic and sedative effects. Used for Anxiety and nervousness, Insomnia and sleep disorders, Restlessness.
At a glance
| Generic name | Passiflora incarnata |
|---|---|
| Also known as | Pascoflair 425mg coated tablets |
| Sponsor | Nutricion Medica S.L. |
| Drug class | Herbal anxiolytic/sedative |
| Target | GABA receptors, serotonin receptors (non-selective) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
The plant extract acts as a mild central nervous system depressant, primarily through enhancement of GABA signaling and modulation of serotonin and dopamine pathways. These mechanisms reduce anxiety, promote relaxation, and improve sleep quality. The active constituents include harmaline, harmine, and various flavonoids that contribute to its calming properties.
Approved indications
- Anxiety and nervousness
- Insomnia and sleep disturbances
- Restlessness
Common side effects
- Drowsiness
- Dizziness
- Headache
- Nausea
Key clinical trials
- Neurexan - a Clinical Trial in Short-Term Insomnia Patients (PHASE2)
- Treatment of Patients Suffering From Nervous Restlessness With PASCOFLAIR®
- Short-term Effects of Passiflora and Meditation on Blood Pressure and Heart Rate (NA)
- Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy (PHASE2)
- Passiflora Extract for Benzodiazepine Withdrawal (PHASE4)
- Three Anxiolytic Drugs Used in Third Molar Surgery (PHASE2, PHASE3)
- Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms (PHASE3)
- Pilot Study on the Efficacy of Pascoflair in an Acute Stressful Situation (TSST) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |